Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David S Stephens

Showing results (11-20 of 150) with videos related to

Pageof 15
Sort By:
The New England Journal of Medicine|May 24, 2023
Global Control of Meningococcal DiseaseDavid S Stephens
Antimicrobial Agents and Chemotherapy|February 27, 2023
Inducible Mega-Mediated Macrolide Resistance Confers Heteroresistance in Streptococcus pneumoniaeSarah Lohsen, David S Stephens
Microorganisms|April 3, 2021
A Narrative Review of the W, X, Y, E, and NG of Meningococcal Disease: Emerging Capsular Groups, Pathotypes, and Global ControlYih-Ling Tzeng, David S Stephens
Frontiers in Cellular and Infection Microbiology|October 7, 2016
Macrolide Resistance in <i>Streptococcus pneumoniae</i>Max R Schroeder, David S Stephens
Current Opinion in Investigational Drugs (London, England : 2000)|September 8, 2006
Serogroup B meningococcal vaccinesShanta M Zimmer, David S Stephens
Biochimica Et Biophysica Acta|May 24, 2015
Antimicrobial peptide resistance in Neisseria meningitidisYih-Ling Tzeng, David S Stephens
The New England Journal of Medicine|January 24, 2020
Good News and Bad News - 4CMenB Vaccine for Group B <i>Neisseria meningitidis</i>Lee H Harrison, David S Stephens
JAMA|September 11, 2020
COVID-19 and the Path to ImmunityDavid S Stephens, M Juliana McElrath
Current Infectious Disease Reports|September 14, 2002
Pathogenesis, Therapy, and Prevention of Meningococcal SepsisDavid S. Stephens, Shanta M. Zimmer
Expert Review of Vaccines|April 24, 2020
Serogroup A meningococcal conjugate vaccines: building sustainable and equitable vaccine strategiesAmy C Sherman, David S Stephens
Pageof 15

Showing results (11-20 of 150) with videos related to

Sort By:
Pageof 15
The New England Journal of Medicine|May 24, 2023
Global Control of Meningococcal DiseaseDavid S Stephens
Antimicrobial Agents and Chemotherapy|February 27, 2023
Inducible Mega-Mediated Macrolide Resistance Confers Heteroresistance in Streptococcus pneumoniaeSarah Lohsen, David S Stephens
Microorganisms|April 3, 2021
A Narrative Review of the W, X, Y, E, and NG of Meningococcal Disease: Emerging Capsular Groups, Pathotypes, and Global ControlYih-Ling Tzeng, David S Stephens
Frontiers in Cellular and Infection Microbiology|October 7, 2016
Macrolide Resistance in <i>Streptococcus pneumoniae</i>Max R Schroeder, David S Stephens
Current Opinion in Investigational Drugs (London, England : 2000)|September 8, 2006
Serogroup B meningococcal vaccinesShanta M Zimmer, David S Stephens
Biochimica Et Biophysica Acta|May 24, 2015
Antimicrobial peptide resistance in Neisseria meningitidisYih-Ling Tzeng, David S Stephens
The New England Journal of Medicine|January 24, 2020
Good News and Bad News - 4CMenB Vaccine for Group B <i>Neisseria meningitidis</i>Lee H Harrison, David S Stephens
JAMA|September 11, 2020
COVID-19 and the Path to ImmunityDavid S Stephens, M Juliana McElrath
Current Infectious Disease Reports|September 14, 2002
Pathogenesis, Therapy, and Prevention of Meningococcal SepsisDavid S. Stephens, Shanta M. Zimmer
Expert Review of Vaccines|April 24, 2020
Serogroup A meningococcal conjugate vaccines: building sustainable and equitable vaccine strategiesAmy C Sherman, David S Stephens
Pageof 15